Clinical Trial

PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Phase II clinical trial of the oral hexavalent reassortant rotavirus attenuated live vaccine (Vero Cells) will be conducted in infants aged 6 to 12 weeks. This study will evaluate the immunogenicity and safety of the investigational vaccine in healthy infants through a randomized, double-blind, active-controlled trial.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-07; most recent amendment 2025-08-18.
Trial Details
NCT Number NCT06967272
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions Rotavirus Gastroenteritis
Enrollment 400 participants
Start Date 2025-01-20
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-08-22